JP2023524149A - Ｃｄ３およびｃｄ２０に対する二重特異性抗体 - Google Patents

Ｃｄ３およびｃｄ２０に対する二重特異性抗体 Download PDF

Info

Publication number
JP2023524149A
JP2023524149A JP2022567357A JP2022567357A JP2023524149A JP 2023524149 A JP2023524149 A JP 2023524149A JP 2022567357 A JP2022567357 A JP 2022567357A JP 2022567357 A JP2022567357 A JP 2022567357A JP 2023524149 A JP2023524149 A JP 2023524149A
Authority
JP
Japan
Prior art keywords
dose
administered
bispecific antibody
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524149A5 (enExample
Inventor
アーマディ，タハムタン
グプタ，マニシュ
リー，トミー・アール
オリヴェリ，ロベルト
デマルコ，ディナ
ヒエムストラ，イーダ
チュー，クリストファー
エリオット，ブライアン
アザリアン，エーダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2023524149A publication Critical patent/JP2023524149A/ja
Publication of JP2023524149A5 publication Critical patent/JP2023524149A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022567357A 2020-05-08 2021-05-07 Ｃｄ３およびｃｄ２０に対する二重特異性抗体 Pending JP2023524149A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063022212P 2020-05-08 2020-05-08
US63/022,212 2020-05-08
US202063078667P 2020-09-15 2020-09-15
US63/078,667 2020-09-15
US202063121690P 2020-12-04 2020-12-04
US63/121,690 2020-12-04
PCT/EP2021/062231 WO2021224499A1 (en) 2020-05-08 2021-05-07 Bispecific antibodies against cd3 and cd20

Publications (2)

Publication Number Publication Date
JP2023524149A true JP2023524149A (ja) 2023-06-08
JP2023524149A5 JP2023524149A5 (enExample) 2024-05-17

Family

ID=75870647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567357A Pending JP2023524149A (ja) 2020-05-08 2021-05-07 Ｃｄ３およびｃｄ２０に対する二重特異性抗体

Country Status (11)

Country Link
US (2) US12435154B2 (enExample)
EP (1) EP4146175A1 (enExample)
JP (1) JP2023524149A (enExample)
KR (1) KR20230008775A (enExample)
CN (1) CN115916166A (enExample)
AU (1) AU2021267402A1 (enExample)
BR (1) BR112022022730A2 (enExample)
CA (1) CA3176436A1 (enExample)
IL (1) IL297986A (enExample)
MX (1) MX2022013797A (enExample)
WO (1) WO2021224499A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813816B1 (ko) * 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) * 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
WO2022053657A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子
IL319999A (en) 2022-11-02 2025-06-01 Genmab As Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
IL324479A (en) 2023-05-15 2026-01-01 Genmab As Methods for treating CD20-expressing B-cell cancers
WO2024236031A1 (en) 2023-05-15 2024-11-21 Genmab A/S Highly purified epcoritamab compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170349657A1 (en) * 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
JP2021513571A (ja) * 2018-02-09 2021-05-27 ジェンマブ アクティーゼルスカブ Ｃｄ３及びｃｄ２０に対する二重特異性抗体を含む医薬組成物及びそれらの使用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2615175B1 (en) 2007-05-31 2018-08-08 Genmab A/S Monovalent human antibodies
WO2008145141A1 (en) 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
CA2689895A1 (en) 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2009212059A (ja) 2008-03-06 2009-09-17 Toshiba Corp 電動軽車両のバッテリ装置
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
BR112016000666A2 (pt) 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligação de antígeno cd3 e cd19 biespecíficos
FR3008667B1 (fr) 2013-07-19 2015-09-04 Bosch Gmbh Robert Unite de commande de freinage
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
WO2015121318A1 (en) 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US20170128448A1 (en) 2014-07-11 2017-05-11 Celgene Corporation Combination therapy for cancer
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN104922668B (zh) 2014-12-10 2019-08-23 信达生物制药(苏州)有限公司 一种稳定的抗vegf抗体制剂及其用途
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
US20160199399A1 (en) 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
CN104922688A (zh) 2015-02-10 2015-09-23 昆明贵研药业有限公司 奥沙利铂的环糊精复合物及制备方法
EP3892302B8 (en) 2015-04-06 2023-10-18 Janssen Pharmaceutica NV Compositions containing ibrutinib
FI3322727T3 (fi) * 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
IL304871A (en) 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
AU2018259078B2 (en) 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
BR112021008486A2 (pt) 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
AU2020328195A1 (en) 2019-08-15 2022-03-03 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
US20230143066A1 (en) 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
KR20230008775A (ko) * 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
JP2023539525A (ja) 2020-09-02 2023-09-14 ジェンマブ エー／エス 抗体療法
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) * 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2022053657A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) * 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
BR112023004319A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma difuso de grandes células b
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CA3243415A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibodies against CD3 and CD20 in a polytherapy regimen for the treatment of diffuse large B-cell lymphoma
KR20240144239A (ko) 2022-01-28 2024-10-02 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
IL319999A (en) 2022-11-02 2025-06-01 Genmab As Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
EP4695293A1 (en) 2023-04-13 2026-02-18 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
IL324479A (en) 2023-05-15 2026-01-01 Genmab As Methods for treating CD20-expressing B-cell cancers
WO2024236031A1 (en) 2023-05-15 2024-11-21 Genmab A/S Highly purified epcoritamab compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170349657A1 (en) * 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
JP2021513571A (ja) * 2018-02-09 2021-05-27 ジェンマブ アクティーゼルスカブ Ｃｄ３及びｃｄ２０に対する二重特異性抗体を含む医薬組成物及びそれらの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INT J HEPMATOL, vol. 106, JPN6025026596, 2017, pages 541 - 551, ISSN: 0005828430 *
PIETERNELLA LUGTENBURG; ET AL: "FIRST-IN-HUMAN, PHASE 1/2 TRIAL TO ASSESS THE SAFETY AND CLINICAL ACTIVITY OF SUBCUTANEOUS GEN3013", BLOOD, vol. VOL:134, SUPPL:1, JPN5023009233, 13 November 2019 (2019-11-13), US, pages 758, ISSN: 0005828428 *
血液内科, vol. 69, no. 1, JPN6025026595, 2014, pages 95 - 101, ISSN: 0005828429 *

Also Published As

Publication number Publication date
EP4146175A1 (en) 2023-03-15
BR112022022730A2 (pt) 2023-02-14
KR20230008775A (ko) 2023-01-16
AU2021267402A1 (en) 2022-11-24
WO2021224499A1 (en) 2021-11-11
MX2022013797A (es) 2022-11-30
CN115916166A (zh) 2023-04-04
US12692320B2 (en) 2026-07-28
US20210371538A1 (en) 2021-12-02
CA3176436A1 (en) 2021-11-11
US12435154B2 (en) 2025-10-07
US20230227570A1 (en) 2023-07-20
IL297986A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US12435154B2 (en) Bispecific antibodies against CD3 and CD20
US11845805B2 (en) Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
JP2023542289A (ja) 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US11858995B2 (en) Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
JP2023542290A (ja) 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US11548952B2 (en) Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
JP2023542092A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US20240368297A1 (en) Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
US20250304689A1 (en) Bispecific antibodies against cd3 and cd20
JP2025537529A (ja) リヒター症候群を治療するためのｃｄ３およびｃｄ２０に対する二重特異性抗体
TW202345895A (zh) 在用於治療瀰漫性大型ｂ細胞淋巴瘤之組合療法中針對ｃｄ３和ｃｄ２０之雙特異性抗體
HK40089030A (en) Bispecific antibodies against cd3 and cd20
US20260125486A1 (en) Methods and compositions for cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260730